|
|
| | Propanoic acid, 2-[2-chloro-5-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]phenoxy]-, (2S)- Basic information |
| | Propanoic acid, 2-[2-chloro-5-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]phenoxy]-, (2S)- Chemical Properties |
| Boiling point | 773.7±60.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | solubility | DMSO: Soluble: =10 mg/ml Ethanol: Sparingly soluble: 1-10 mg/ml | | pka | 3.11±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Propanoic acid, 2-[2-chloro-5-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]phenoxy]-, (2S)- Usage And Synthesis |
| Description | SR10221 is a PPARγ inverse-agonist. SR10221 represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines. | | Uses | SR10221, a noncovalent inverse agonist of PPARγ, represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines[1]. | | References | [1] Sean Irwin, et al. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists. J Biol Chem. 2022 Nov;298(11):102539. DOI:10.1016/j.jbc.2022.102539 |
| | Propanoic acid, 2-[2-chloro-5-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]phenoxy]-, (2S)- Preparation Products And Raw materials |
|